Innovative strategies to promote biomedical HIV prevention uptake and retention among high-risk adults at drinking venues in Kenya and Uganda
Project Number5R01AA030464-03
Contact PI/Project LeaderCHAMIE, GABRIEL
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Project Summary
HIV incidence remains unacceptably high in sub-Saharan Africa (SSA) due in part to inadequate access,
uptake, and retention in biomedical HIV prevention services, including pre- and post-exposure prophylaxis
(PrEP/PEP), among persons at increased HIV risk. Alcohol use is a common risk factor for both HIV
acquisition and poor HIV prevention uptake and retention in SSA. Interventions that promote biomedical HIV
prevention among persons with heavy alcohol use and their sexual partners are urgently needed.
Alcohol-serving drinking venues play an important role as sites of HIV transmission in SSA and are ideal sites
to engage women and men at increased risk of HIV in biomedical prevention services. However, despite long-
standing awareness of drinking venues as transmission “hot spots”, few interventions exist to reach and
engage persons in PrEP and PEP from drinking venues in SSA. Major barriers to reaching and engaging
persons at high risk of HIV from community settings such as drinking venues in HIV testing – a critical first step
to accessing biomedical HIV prevention – include HIV-associated stigma and poor perceptions of risk. To
address these barriers, we have developed a mobilization strategy of integrating HIV testing within multi-
disease screening to recruit >2,000 people from drinking venues in Kenya and Uganda, reaching >75% of
adults recruited for HIV testing. We now need to determine whether multi-disease mobilization can promote
uptake of HIV prevention for adults at drinking venues in the context of new biomedical prevention options.
Following uptake of biomedical HIV prevention, persons with heavy alcohol use face challenges with retention
in care and adherence to PrEP/PEP. We have adapted a brief alcohol counseling intervention (Health Living)
to reduce alcohol use and promote antiretroviral therapy (ART) adherence and HIV viral suppression among
persons with HIV in Kenya and Uganda. We now need to determine whether this intervention can promote
retention in biomedical prevention and PrEP/PEP adherence among adults with heavy alcohol use.
The project will rigorously test innovative interventions in Kenya and Uganda to increase uptake and use of
biomedical HIV prevention, and assess facilitators, barriers, and cost-effectiveness of these approaches.
The project will have the following aims: Aim 1: Compare the effectiveness of two mobilization strategies to
increase uptake of biomedical HIV prevention among adults at drinking venues. Aim 2: Determine the efficacy
of the Healthy Living Intervention (HLI) to reduce heavy alcohol use vs. standard care (control) on retention in
biomedical HIV prevention in a randomized trial among adults with heavy alcohol use. Aim 3: Determine the
cost-effectiveness of interventions that increase biomedical HIV prevention uptake (Aim 1) and retention (Aim
2) among adults at high-risk for HIV who attend drinking venues.
The proposed research will address the critical intersection of alcohol use and HIV risk in SSA, by promoting
reach, uptake and retention in biomedical HIV prevention and exploring associated facilitators and barriers.
Public Health Relevance Statement
Project Narrative
Alcohol use is a common risk factor for both HIV acquisition and poor uptake and use of effective biomedical
HIV prevention options, including pre- and post-exposure prophylaxis, in sub-Saharan Africa. This study will
test innovative interventions to increase uptake and use of biomedical HIV prevention options by engaging
women and men at drinking venues in rural Kenya and Uganda in care and evaluating a brief alcohol
counseling intervention among adults with heavy alcohol use at high risk for HIV, while gaining insights into the
facilitators, barriers, and cost-effectiveness of these approaches.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAddressAdherenceAdultAfrica South of the SaharaAlcohol consumptionAlcoholsAnti-Retroviral AgentsAwarenessCaringCommunitiesConsumptionCounselingCountryDataDiseaseEffectiveness of InterventionsFaceHIVHIV SeropositivityHIV riskHIV therapyHealthHeavy DrinkingHot SpotHuman immunodeficiency virus testIncidenceInjectableInterventionInterviewKenyaOralParticipantPerceptionPersonsPlayPrevalencePreventionProphylactic treatmentResearchRiskRisk FactorsRoleRuralSamplingSexual PartnersSiteTestingTimeUgandaUnsafe SexViralWomanalcohol use initiationantiretroviral therapyarmbarrier to testingcommunity settingcompare effectivenesscost effectivenesscost estimatedrinkingeffectiveness measureeffectiveness trialefficacy evaluationhigh riskinnovationinsightmenphosphatidylethanolpre-exposure prophylaxisprevention serviceprimary outcomerandomized trialrecruitreduced alcohol userisk perceptionscreeningsecondary outcomesocial stigmastandard caretesting uptaketherapy adherencetransactional sextransmission processuptake
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
01-September-2022
Project End Date
30-June-2027
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$591,494
Direct Costs
$481,705
Indirect Costs
$109,789
Year
Funding IC
FY Total Cost by IC
2024
National Institute on Alcohol Abuse and Alcoholism
$591,494
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AA030464-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AA030464-03
Patents
No Patents information available for 5R01AA030464-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AA030464-03
Clinical Studies
No Clinical Studies information available for 5R01AA030464-03
News and More
Related News Releases
No news release information available for 5R01AA030464-03
History
No Historical information available for 5R01AA030464-03
Similar Projects
No Similar Projects information available for 5R01AA030464-03